No One Talks about Vasoplegia
10 January, 2025 3:00 p.m. to 4:00 p.m. EST
The presence of vasoplegia after cardiac surgery has an important influence on the early and longer-term post-operative morbidity and mortality. Some of the difficulty in the treatment of patients with vasoplegia lies in the lack of a unified definition. There are many factors that affect the incidence of vasoplegia and the response to treatment. While many treatment centers use different definitions of vasoplegia, the difficulty lies in clearly identify the underlying mechanisms, predictors, outcomes and treatment of this problem. In this webinar we will discuss what is understood as the pathophysiology of vasoplegia and its implications in the management of patients receiving short and long-term mechanical circulatory support. Finally, we will discuss the controversies that exists in the treatment of vasoplegia.
Moderators
Phyllis Billia, MD, PhD
Mitesh Badiwala, MD, PhD, FRCSC
Presentations
How Do We Define 'Vasoplegia'
Presented by Eric de Waal, MD, PhD
Pathophysiology of Vasoplegia – Arterial Versus Cardiomyocyte Consequences
Presented by Katharina Wassilew, MD, MHBA
Implications of Vasoplegia in Short and Long-Term MCS
Presented by Anju Bhardwaj, MD
Controversies in the Treatment of Vasoplegia
Presented by Douglas Jennings, PharmD
